1.63
-0.03(-1.81%)
Currency In USD
| Previous Close | 1.66 |
| Open | 1.62 |
| Day High | 1.65 |
| Day Low | 1.57 |
| 52-Week High | 3.44 |
| 52-Week Low | 0.98 |
| Volume | 44,218 |
| Average Volume | 268,339 |
| Market Cap | 65.74M |
| PE | -8.58 |
| EPS | -0.19 |
| Moving Average 50 Days | 1.91 |
| Moving Average 200 Days | 1.89 |
| Change | -0.03 |
If you invested $1000 in BeyondSpring Inc. (BYSI) since IPO date, it would be worth $97.02 as of January 14, 2026 at a share price of $1.63. Whereas If you bought $1000 worth of BeyondSpring Inc. (BYSI) shares 5 years ago, it would be worth $125.87 as of January 14, 2026 at a share price of $1.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec.
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent sur
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
GlobeNewswire Inc.
Jul 07, 2025 11:00 AM GMT
In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in non-irradiated lesions.Biomarker